Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Invested Capital (2016 - 2025)

Historic Invested Capital for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $24.0 million.

  • Cytosorbents' Invested Capital rose 8273.29% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 8273.29%. This contributed to the annual value of $11.1 million for FY2024, which is 6106.1% down from last year.
  • According to the latest figures from Q3 2025, Cytosorbents' Invested Capital is $24.0 million, which was up 8273.29% from $11.6 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' Invested Capital registered a high of $77.3 million during Q1 2021, and its lowest value of $11.1 million during Q4 2024.
  • Moreover, its 5-year median value for Invested Capital was $29.5 million (2023), whereas its average is $36.5 million.
  • In the last 5 years, Cytosorbents' Invested Capital skyrocketed by 11224.03% in 2021 and then plummeted by 6106.1% in 2024.
  • Over the past 5 years, Cytosorbents' Invested Capital (Quarter) stood at $62.6 million in 2021, then crashed by 43.47% to $35.4 million in 2022, then decreased by 19.37% to $28.5 million in 2023, then tumbled by 61.06% to $11.1 million in 2024, then skyrocketed by 116.26% to $24.0 million in 2025.
  • Its Invested Capital was $24.0 million in Q3 2025, compared to $11.6 million in Q2 2025 and $14.5 million in Q1 2025.